After a controversial development and testing period, Flibanserin is now turning out to be a marketplace disappointment.
Here’s a link to the recent metastudy of research into the effectiveness of workplace drug testing that is mentioned in the Slate article on that subject that we’re reading this week: “How Effective is Drug Testing as a Workplace Safety Strategy? A Systematic Review of the Evidence.”
The latest move in the slow march away from the War on Drugs and towards harm reduction policies: A Boston nonprofit plans to, “Open a room in March with a nurse, some soft chairs and basic life-saving equipment — a place where heroin users can ride out their high, under medical supervision.”
The latest in the New York Times about the Case and Deaton white mortality data we were discussing in seminar: a couple of letters to the editor exploring possible explanations.
With a sample size of about 68,000, you’ve got pretty solid data.
The Indian government is moving away from family planning policies promoting tubal ligation and toward a system of free injectable birth control for women.
The story at NPR also includes links to related stories about Adderall use and abuse.
Regarding our discussion last night of Allen Frances’ past connections to Johnson & Johnson, here’s this blog article. I know nothing about its author or its authority; evaluate those yourself, keeping in mind anyone can put anything on the interwebs.
Among our topics for discussion this week are business strategies pursued by the pharmaceutical industry. Along those lines, see this analysis of the incentives for Big Pharma that grow out of the interplay between the F.D.A. approval process and the patent system: “Why Preventing Cancer Is Not the Priority in Drug Development.”
In the New York Times this week: “Want Viagra? Proposed Kentucky Law Would Require Note From Spouse.”